We use necessary system cookies for the correct functioning of the website and optional Google Analytics cookies to obtain visit statistics.

Cookies config

  • Necessary

    The necessary cookies are absolutely essential for the website to work properly. This category only includes cookies that guarantee basic website security and functionality. These cookies do not store any personal information.

    _GRECAPTCHAgoogle.comOwnprovide antispam protection with the reCaptcha service6 months
    cc_cookie_acceptfidmag.orgOwnUsada per confirmar que l'usuari ha confirmat / refusat les cookies (i quins tipus accepta)1 any
    WEB_SESSIONfidmag.orgOwnCookie técnica: cookie de sessió PHP. Guarda l'id de sessió d' acabar la sessió

  • Analisys

    Analytical cookies are used to understand how visitors interact with the website. These cookies help to provide information on meters, the name of visitors, the percentage of bounces, the font of the traffic, etc.

    _gaGoogle AnalyticsFrom third partiesCookie d'anàlisi o mesurament: Identifica els usuaris i proporciona informació sobre com els usuaris troben la pàgina web i com la utilitzen per a realització d'Informes estadístics2 anys
    _gat_gtag_UA_141706552_1Google AnalyticsFrom third partiesCookie d'anàlisi o mesurament: Tracking per part de google per google analytics1 minut
    _gidGoogle AnalyticsFrom third partiesCookie d'anàlisi o mesurament: S'usa per limitar el percentatge de sol·licituds24 hores

ConfigureReject allAccept


Deep brain stimulation for patients with treatment-resistant schizophrenia: a multicentre prospective study


Deep brain stimulation (DBS) in which high frequency electrical pulses are delivered to specific brain areas through implanted electrodes, has an established place in neurological disorders. It has also demonstrated encouraging results in refractory forms of obsessive-compulsive and depression. Its use in patients with treatment-resistant schizophrenia is of considerable current interest, but evidence is preliminary. The first and so far, the only completed formal trial (N=7), carried out partly by members of the current research group, found preliminary evidence of effectiveness in 3 treatment resistant schizophrenia patients stimulating the nucleus accumbens, a dopamine-rich site of the brain.

The present study aims to further examine the efficacy and safety of DBS in the nucleus accumbens (N=4 patients) and to explore its potential effectiveness in a new site, the ventral tegmental area (N=4), the brain area that gives rise to dopamine projections relevant to schizophrenia. The study will follow the design of our earlier trial: after a 6 month (or longer) open treatment phase, patients with predetermined criteria for improvement will undergo a 12-week crossover phase where the current will be switched off for half the time under double-blind conditions. Extended post-trial follow-up (12+ months) will monitor long term adverse psychiatric effects.


97.965,00 €


Logo Fundació La Marato


We are part of
HH Província España
Contact us

Avda. Jordà, 8, 08035 Barcelona
Contact phone: 935 480 105
Online contact 



Reconocimientos a la calidad y la excelencia
Última modificación: 12/07/2024